|
**Overview**: **Liver Panel 2 Profile****Introduction**: The Liver Panel 2 Profile is a diagnostic tool designed for extended liver function screening using serum samples. Associated with conditions like hepatitis and cirrhosis, these disorders present with jaundice, fatigue, and severe complications if untreated, particularly in individuals with suspected liver disease. Per the 2023 Biochemistry guidelines, the test employs biochemistry with spectrophotometry technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for liver function monitoring in clinical settings. This diagnostic falls under liver function monitoring and targets individuals with suspected liver disease, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: LFT 2 Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1970s by clinical labs, this test advanced extended liver function diagnostics.**Purpose**: The test screens for 15 parameters including total bilirubin to guide liver assessment, assess liver function, and inform treatment and prevention strategies.**Test Parameters**: 1. Total Bilirubin, 2. Direct Bilirubin, 3. AST, 4. ALT, 5. ALP, 6. Total Protein, 7. Albumin, 8. Globulin, 9. GGT, 10. Prothrombin Time, 11. INR, 12. LDH, 13. Haptoglobin, 14. Ceruloplasmin, 15. Alpha-1-Antitrypsin.**Pretest Condition**: Fasting 10-12 hours required; patients should report jaundice, fatigue, or recent liver symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on jaundice, fatigue, prior liver reactions, or family history of liver disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated liver disease including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible liver disease, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in hepatology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Imaging or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry Guidelines 2023, Journal of Hepatology 2024, Chemistry 2025. |
